Toth Financial Advisory’s NovoCure NVCR Stock Holding History

Toth Financial Advisory’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-75	Closed	-$1.21K	–	774
2023 Q3	$1.21K	Hold	75	–	–	﹤0.01%	700
2023 Q2	$3.11K	Hold	75	–	–	﹤0.01%	596
2023 Q1	$4.51K	Hold	75	–	–	﹤0.01%	553
2022 Q4	$5.5K	Hold	75	–	–	﹤0.01%	496
2022 Q3	$6K	Hold	75	–	–	﹤0.01%	533
2022 Q2	$5K	Hold	75	–	–	﹤0.01%	514
2022 Q1	$6K	Hold	75	–	–	﹤0.01%	522
2021 Q4	$6K	Hold	75	–	–	﹤0.01%	543
2021 Q3	$9K	Hold	75	–	–	﹤0.01%	497
2021 Q2	$17K	Hold	75	–	–	﹤0.01%	403
2021 Q1	$10K	Hold	75	–	–	﹤0.01%	469
2020 Q4	$13K	Buy	75 +45	+150%	+$6.16K	﹤0.01%	384
2020 Q3	$3K	Buy	+30	New	+$2.4K	﹤0.01%	458

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Toth Financial Advisory's NVCR Position: Q4 2023 in Review

Toth Financial Advisory sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 75 shares — an estimated $1.21K sold.

Toth Financial Advisory first reported a position in NVCR in Q3 2020 and held it in 13 quarters. The position peaked at $17K in Q2 2021. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

Toth Financial Advisory reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
Toth Financial Advisory sold 75 NovoCure shares in Q4 2023, an estimated $1.21K.
Toth Financial Advisory first reported a position in NovoCure in Q3 2020 and held it in 13 quarters.
Toth Financial Advisory's NovoCure position peaked at $17K in Q2 2021.
219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Toth Financial Advisory's 13F filing for Q4 2023, filed 26 Jan 2024.